nach oben

Current Treatment Options in Rheumatology

Erschienen in:

01.03.2018 | Lupus (S Keeling, Section Editor)

Treatment of Systemic Lupus Erythematosus (SLE) in Pregnancy

verfasst von: Erin Shirley, BS, Eliza F. Chakravarty, MD, MS

Erschienen in: Current Treatment Options in Rheumatology | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of review

To identify known teratogenic medications that may be used to treat SLE and discuss alternative therapeutics that can be used throughout pregnancy in order to manage maternal autoimmune diseases.

Recent findings

Teratogenic immunosuppressive medications include methotrexate, mycophenolatemofetil, and cyclophosphamide. In anticipation of pregnancy, such medications should be discontinued and replaced with immunosuppressive medications including azathioprine and cyclosporine and assessed for disease stability.

Summary

Pregnancy is an important aspect to women’s lives, and a diagnosis of SLE should not necessarily preclude the ability to bear children. Pregnancy outcomes among SLE women are favorable when disease is well controlled prior to conception and teratogenic medications are avoided. Several immunosuppressive therapies that are compatible with pregnancy are available to treat flares that may occur during pregnancy. Hydroxychloroquine use throughout pregnancy is associated with improved outcomes for both mother and infant. Risks of medication use need to be balanced with risks of active maternal disease.

Centers for Disease Control and Prevention(CDC). Update on overall prevalence of major birth defects, Atlanta, Georgia, 1978-2005. MMWR Morb Mortal Wkly Rep. 2008;57:1–5.

Ostensen M. Preconception counseling. Rheum Dis Clin N Am. 2017;43(2):189–99. https://doi.org/10.1016/j.rdc.2016.12.003.CrossRef

Knight CL, Nelson-Piercy C. Management of systemic lupus erythematosus during pregnancy: challenges and solutions. Open Access Rheumatol 2017; Nar 10. https://doi.org/10.2147/OARRR.S878(.

•• Buyon JP, Kim MY, Guerra MM, Laskin CA, et al. Predictors of pregnancy outcomes in patients with lupus: a cohort study. Ann Intern Med. 2015;163(3):153–63. This is an outstanding prospective study of pregnancies in women with SLE. The study was designed to exclude pregnancies with known risk factors so that the role of underlying SLE on pregnancy outcomes could be examined more closely

Tedeschi SK, Guan H, Fine A, Costenbader KH, Bermas B. Organ-specific systemic lupus erythematosus activity during pregnancy is associated with adverse pregnancy outcomes. ClinRheumatol. 2016;35(7):1725–32.

Peart E, Clowse ME. Systemic lupus erythematosus and pregnancy outcomes: an update and review of the literature. CurrOpinRheumatol. 2014;26(2):118–23.

https://www.mycophenolaterems.com/

Kozma C, Ramasethu J. Methotrexate and misoprostol teratogenicity: further expansion of the clinical manifestations. Am J Med Genet A. 2011;155A(7):1723–8. https://doi.org/10.1002/ajmg.a.34037.CrossRefPubMed

Lewden B, Vial T, Elefant E, Nelva A, Carlier P, Descotes J, et al. Low dose weekly methotrexate in the first trimester of pregnancy: results of a French collaborative study. J Rheumatol. 2004;31(12):2360–5.

10.

•• Weber-Schoendorfer C, Chambers C, Wacker E, Beghin D, Bernard N, et al. Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study. Arthritis Rheumatol. 2014;66:1101–10. This is a well performed, prospective study of pregnant outcomes following early exposure to methotrexate at doses typically used for rheumatic diseasesCrossRefPubMed

11.

Sifonis NM, Coscia LA, Constantinescu S, Lavelanet AF, Moritz MJ, Armenti VT. Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolatemofetil or sirolimus. Transplantation. 2006;82(12):1698–702. https://doi.org/10.1097/01.tp.0000252683.74584.29.CrossRef

12.

Anderka MT, Lin AE, Abuelo DN, Mitchell AA, Rasmussen SA. Reviewing the evidence for mycophenolatemofetil as a new teratogen: case report and review of the literature. Am J Med Genet. 2009;149A(6):1241–8. https://doi.org/10.1002/ajmg.a.32685.CrossRefPubMed

13.

Coscia LA, Constantinescu S, Davison JM, Moritz MJ, Armenti VT. Immunosuppressive drugs and fetal outcome. Best Pract Res Clin Obstet Gynecol. 2014;28(8):1174–87. https://doi.org/10.1016/j.bpobgyn.2014.07.020.CrossRef

14.

Coscia LA, Armenti DP, King RW, Sifonis NM, Constantinescu S, Moritz MJ. Update on the teratogenicity of maternal mycophenolatemofetil. J Pediatr Genet. 2015;4(2):42–55. https://doi.org/10.1055/s-0035-1556743.CrossRefPubMedPubMedCentral

15.

Clowse ME, Madger LS, Petri M. Cyclophosphamide for lupus during pregnancy. Lupus. 2005;14(8):593–7. https://doi.org/10.1191/0961203305lu2169oa.CrossRefPubMed

16.

Mok CC, Ying KY, Tang S, Leung CY, Lee KW, Ng WL, et al. Predictors and outcomes of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum. 2004;50(8):2559–68. https://doi.org/10.1002/art.20364.

17.

Saarikoski S, Seppala M. Immunosuppression during pregnancy: transmission of azathioprine and its metabolites from mother to fetus. Am J ObstetGynecol. 1973;115(8):1100–6. https://doi.org/10.1016/0002-9378(73)90559-0.CrossRef

18.

Shah S, Verma P. Overview of pregnancy in renal transplant patients. Int J Nephrol 2016; doi/https://doi.org/10.1155/2016/4539342.

19.

Ostensen M, Khamashta M, Lockshin M, Parke A, et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther. 2006;8(3):209. https://doi.org/10.1186/ar1957.CrossRefPubMedPubMedCentral

20.

Stanhope TJ, White WM, Moder KG, Smyth A, Garovic VD. Obstetric neprhology: lupus and lupus nephritis in pregnancy. Clin J Am SocNeprhol. 2012;7(12):2089–99. https://doi.org/10.2215/CJN.12441211.CrossRef

21.

• Mok CC. Pro: The use of calcinurin inhibitors in the treatment of lupus nephritis. Nephrol Dial Trans. 2016;31(10):1561–6. This is a very well written review article on the use of calcinurin inhibitors for lupus nephritis by one of the worldwide experts in the field. While it does not discuss pregnancy per se, it provides an excellent guideline of how to use the medications in SLECrossRef

22.

Webster P, Wardle A, Bramham K, Webster L, Nelson-Piercy C, Lightstone L. Tacrolimus is and effective treatment for lupus nephritis in pregnancy. Lupus. 2014;23(11):1192–6. https://doi.org/10.1177/0961203314540353.CrossRefPubMed

23.

Ruiz-Irastorza G, Danza A, Perales I, Villar I, Garcia M, Delgado S, et al. Prednisone in lupus nephritis: how much is enough? Autoimmun Rev. 2014;13(2):206–14. https://doi.org/10.1016/j.autrev.2013.10.013.

24.

Venkataramanan R, Koneru B, Wang CCP, et al. Cyclosporine and its metabolites in mother and baby. Transplantation. 1988;46(3):468–9. https://doi.org/10.1097/00007890-198809000-00032.CrossRefPubMedPubMedCentral

25.

Pickrell MD, Sawers R, Michael J. Pregnancy after renal transplantation: severe intra-uterine growth retardation during treatment with cyclosporine. Br Med J. 1988;296(6625):825. https://doi.org/10.1136/bmj.296.6625.825.CrossRef

26.

Paziana K, Del Monaco M, Cardonick E, Moritz M, Keller M, Smith B, et al. Ciclosporin use during pregnancy. Drug Saf. 2013;36(5):279–94. https://doi.org/10.1007/s40264-013-0034-x.

27.

Schen FP, Stalloone G, Schena A, et al. TransplImmunol. 2002;9:161–4.

28.

• Sandhu VK, Wallace DJ, Weisman MH. Monoclonal antibodies, systemic lupus erythematosus, and pregnancy: insights from an open label study. J Rheumatol. 2015;42(4):728–30. A well written editorial discussing theoretical risks and benefits of ongoing use of belimumab in pregnancyCrossRefPubMed

29.

Chakravarty EF, Murray ER, Kelman A, Farmer P. Pregnancy outcomes after maternal exposure to rituximab. Blood. 2011;117(5):1499–506. https://doi.org/10.1182/blood-2010-07-295444.CrossRefPubMed

30.

Skuladottir H, Wilcox AJ, Ma C, Lammer EJ, Rasmussen SA, Werler MM, et al. Corticosteroid use and risk of orofacial clefts. Birth Defects Res A ClinMolTeratol. 2014;100(6):499–506. https://doi.org/10.1002/bdra.23248.

31.

Stone CT. Safety of chloroquine in pregnancy. JAMA. 1965;192(3):260. https://doi.org/10.1001/jama.1965.03080160080030.CrossRefPubMed

32.

Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med. 1991;324(3):150–4.CrossRef

33.

Levy RA, Vilela VS, Cataldo MJ, Ramos RC, et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Supus. 2001;10(6):401–4.

Titel: Treatment of Systemic Lupus Erythematosus (SLE) in Pregnancy
verfasst von: Erin Shirley, BS
Eliza F. Chakravarty, MD, MS
Publikationsdatum: 01.03.2018
Verlag: Springer International Publishing
Erschienen in: Current Treatment Options in Rheumatology / Ausgabe 1/2018
Elektronische ISSN: 2198-6002
DOI: https://doi.org/10.1007/s40674-018-0085-3

Ocular Involvement in Sjögren’s Syndrome: Advances in Therapy

Open Access
Other CTD: Inflammatory Myopathies and Sjogren's (P Basharat, Section Editor)

Treat to Target in Juvenile Idiopathic Arthritis: Challenges and Opportunities

Pediatric Rheumatology (M Becker and J Harris, Section Editors)

Addressing Mental Health in Pediatric Rheumatology

Pediatric Rheumatology (M Becker and J Harris, Section Editors)

An Update on the Treatment of Pediatric Autoimmune Encephalitis

Pediatric Rheumatology (M Becker and J Harris, Section Editors)

Biologic Therapy in the Treatment of Sjögren’s Syndrome: a Clinical Perspective

Other CTD: Inflammatory Myopathies and Sjogren's (P Basharat, Section Editor)

Current Understanding of Optimal Self-Management Strategies and Approaches for Youth With Amplified Musculoskeletal Pain Conditions

Pediatric Rheumatology (M Becker and J Harris, Section Editors)

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie erweitert durch Fallbeispiele, Videos und Abbildungen. Zur Fortbildung und Wissenserweiterung, verfasst und geprüft von Expertinnen und Experten der Gesellschaft für Arthroskopie und Gelenkchirurgie (AGA).

Jetzt entdecken!

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Viele Versäumnisse bei Psoriasis-Arthritis

17.04.2025
Psoriasis-Arthritis
Nachrichten

Menschen mit Psoriasis-Arthritis (PsA) müssen länger auf die Diagnose warten und werden zögerlicher behandelt als an rheumatoider Arthritis (RA) Erkrankte. Diese Defizite hat eine Untersuchung in Großbritannien aufgedeckt.

Yoga gegen Kniearthrose nicht schlechter als Krafttraining

15.04.2025
Gonarthrose
Nachrichten

Menschen mit Gonarthrose profitieren von Yogaübungen nicht weniger als von gezielten Kräftigungsübungen für die lädierten Knie. In einer Vergleichsstudie haben sich für Yogis und Yoginis sogar einige Vorteile ergeben.

Muskelrelaxanzien wohl nur bei akuten Kreuzschmerzen hilfreich

14.04.2025
Rückenschmerzen
Nachrichten

Bei akuten Rückenschmerzen können Muskelrelaxanzien, eventuell in Kombination mit NSAR, zur Schmerzlinderung beitragen. Wegen der Nebenwirkungen wird jedoch empfohlen, die Medikamente nur über wenige Tage einzusetzen.

Wie bereits der virtuelle "Blick ins Grüne" Schmerzen lindern kann

07.04.2025
Nichtmedikamentöse Schmerztherapie
Nachrichten

Dass der Blick in die Natur Menschen dazu bringen kann, Schmerzen weniger stark zu empfinden, konnte bereits mehrfach nachgewiesen werden. Jetzt ließen sich in einer experimentellen Studie sogar allein durch das Betrachten von Videos mit Naturszenen analgetische Effekte erzeugen.

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Treatment of Systemic Lupus Erythematosus (SLE) in Pregnancy